Stem cell factor receptor (c-kit, CD117) is expressed on blast cells from most immature types of acute myeloid mallignancies but is also a characteristic of a subset of acute promyelocytic leukaemia.
Investigating 208 patients with acute haematological malignancies, we found that stem cell factor receptor (SCFR) was expressed on high numbers of blast cells from the vast majority of patients (93%) with refractory anaemia with excess of blasts in transformation. SCFR was also detected in 62% of AMLs, in which it was directly associated to the expression of CD7, interleukin 6 receptor and CD34, and inversely to that of CD11b and CD14. SCFR-positive cases were preferentially represented in AML-M1 (70%) and in AML-M2 (83%) subsets, whereas only 45% of the remaining samples (M3-M4-M5) exhibited SCFR positively. Interestingly, 50% of cases with acute promyelocytic leukaemia expressed SCFR and this molecule was heterogenously regulated by in vitro treatment with all-trans retinoic acid.
Di Noto
R
R
Divisone di Oncologia Sperimentale C. Immunologia, Istituto Nazionale dei Tumori, Fondazione G. Pascale, Naples, Italy.
Lo Pardo
C
C
Schiavone
E M
EM
Manzo
C
C
Vacca
C
C
Ferrara
F
F
Del Vecchio
L
L
D000208:Acute Disease; D006801:Humans; D007951:Leukemia, Myeloid / Q000378:metabolism* / Q000473:pathology; D015473:Leukemia, Promyelocytic, Acute / Q000378:metabolism* / Q000473:pathology; D016131:Lymphocyte Subsets / Q000473:pathology; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism*; D014212:Tretinoin / Q000494:pharmacology
D014212:Tretinoin; D019009:Proto-Oncogene Proteins c-kit